Scientific deep-dive

Ozempic and Sleep: Insomnia, Sleep Quality & Sleep Apnea (2026)

Does Ozempic affect sleep? Insomnia isn't a prominently labeled side effect of semaglutide, but it can disrupt sleep indirectly. The weight loss it drives often improves obstructive sleep apnea — tirzepatide (Zepbound) is now FDA-approved for moderate-to-severe OSA. A nuanced, prescriber-directed guide.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
8 min read·5 citations

The honest answer is that Ozempic's relationship with sleep runs in two directions. On one hand, insomnia is not a prominently labeled common side effect of semaglutide, and when people do report disturbed sleep it is usually indirect — nighttime nausea or reflux, needing the bathroom, low blood sugar at night (especially when Ozempic is combined with insulin or a sulfonylurea), under-eating, or anxiety. On the other hand, the weight loss that GLP-1 medicines drive often improves sleep, particularly by reducing the severity of obstructive sleep apnea (OSA) and lifting overall sleep quality. The evidence here is real: the SURMOUNT-OSA trial showed major OSA improvement with the related drug tirzepatide, and in December 2024 the FDA approved Zepbound (tirzepatide) for moderate-to-severe OSA in adults with obesity — the first medication approved for that condition.[1] Semaglutide itself is not specifically OSA-approved, but the same weight-loss pathway that helps with apnea applies. This guide covers both directions honestly, plus practical, prescriber-directed steps for protecting your sleep. Ozempic is semaglutide; see our Ozempic drug page and the broader Ozempic side effects guide for the full picture. This is general educational information, not medical advice — your prescriber manages your care.

About this article

The sleep-apnea evidence below was verified against primary sources: the SURMOUNT-OSA randomized trial of tirzepatide in obstructive sleep apnea and obesity (Malhotra and colleagues, New England Journal of Medicine, 2024), the SCALE Sleep Apnea trial of the GLP-1 medicine liraglutide (Blackman and colleagues), and a peer-reviewed narrative review of GLP-1 receptor agonists in obesity-related OSA — not an AI paraphrase or a third-party blog. Statements about whether sleep problems are a labeled side effect of semaglutide were checked against the FDA prescribing information on DailyMed (NIH) and the MedlinePlus consumer summary. A key nuance: the FDA approval for treating moderate-to-severe OSA applies to tirzepatide (Zepbound), not to semaglutide; we say so plainly. Individual responses vary, and any sleep disturbance on Ozempic is usually secondary to other effects rather than a direct labeled action of the drug. For the full side-effect profile see Ozempic side effects and the Ozempic drug page. This is general information, not medical advice — your prescriber individualizes your care.

Can Ozempic disrupt your sleep?

Sometimes — but it is worth being precise about what the evidence does and does not show. Insomnia is not a prominently labeled common side effect of semaglutide. It does not appear as a headline adverse reaction in the way that nausea, diarrhea, vomiting, and constipation do, and the consumer summaries do not flag sleeplessness as a typical effect.[4] So when someone sleeps poorly after starting Ozempic, the disturbance is usually indirect — a downstream consequence of the drug's other effects rather than a direct action on the brain's sleep machinery. The reports that do exist are largely anecdotal or secondary, which is an important distinction: it means the problem is often addressable by fixing the underlying driver.

The most common indirect routes to disrupted sleep on Ozempic are nighttime gastrointestinal symptoms (nausea, reflux, or needing the bathroom from diarrhea), low blood sugar overnight — which can cause night sweats and waking, and which is far more likely when semaglutide is combined with insulin or a sulfonylureaunder-eating during the day so that hunger or a metabolic dip interferes with rest, and anxiety around starting a new medicine.[4] None of these is the drug "causing insomnia" in a direct pharmacologic sense; each is a knock-on effect you and your prescriber can usually manage.

How Ozempic (semaglutide) can indirectly disrupt sleep — the likely route, what's happening, and what generally helps. Sleep disturbance is not a prominently labeled side effect; these are mostly secondary effects. All management is prescriber-directed — do not change your dose or other medications on your own.
Possible routeWhat's happeningWhat generally helps
Nighttime GI symptomsNausea, reflux, or diarrhea (needing the bathroom) can interrupt sleep, especially early on and after a dose increaseLighter, earlier evening meals; let GI symptoms ease as you adapt; tell your prescriber if they persist
Low blood sugar at nightOvernight hypoglycemia can cause night sweats and waking — much more likely with insulin or a sulfonylureaPrescriber may adjust the insulin/sulfonylurea dose or timing; follow your clinician's plan for treating lows
Under-eating during the dayA sharp appetite drop can leave you under-fueled, so hunger or a metabolic dip disturbs restRegular, balanced, protein-forward meals even when the hunger cue is gone; avoid skipping meals
Anxiety around a new medicineWorry about side effects or weight changes can fuel a temporary bout of poor sleepBasic sleep hygiene; raise persistent anxiety or sleeplessness with your prescriber

Can Ozempic improve your sleep?

Yes — and this is the better-evidenced direction. The weight loss that GLP-1 medicines produce often improves sleep, and the clearest example is obstructive sleep apnea (OSA), in which the upper airway repeatedly narrows or collapses during sleep, fragmenting rest and dropping oxygen levels. OSA is strongly linked to excess weight, so losing weight tends to reduce its severity — fewer breathing interruptions per hour, better oxygenation, and often better-quality, less-fragmented sleep. Beyond apnea, many people simply find that as their weight comes down their overall sleep quality improves.

The trial evidence is concrete. SURMOUNT-OSA, published in the New England Journal of Medicine in 2024, tested the related GLP-1/GIP medicine tirzepatide in adults with obesity and moderate-to-severe OSA and found a large reduction in the apnea-hypopnea index (the standard measure of breathing interruptions per hour) compared with placebo.[1] On the strength of that trial, the FDA in December 2024 approved Zepbound (tirzepatide) for moderate-to-severe OSA in adults with obesity — the first drug ever approved to treat the condition.[1] The principle was already visible with an earlier GLP-1 medicine: the SCALE Sleep Apnea trial showed that weight loss on liraglutide 3.0 mg reduced OSA severity versus placebo.[2] A peer-reviewed review of GLP-1 receptor agonists in obesity-related OSA reaches the same broad conclusion — the airway benefit travels with the weight loss.[3]

Important distinction

The FDA approval to treat moderate-to-severe OSA is for Zepbound (tirzepatide), not for semaglutide.[1] Ozempic (semaglutide) is not specifically approved for sleep apnea. However, semaglutide drives clinically meaningful weight loss, and because the OSA benefit largely tracks with weight loss, semaglutide-associated weight loss similarly tends to reduce OSA severity.[2][3] If you have sleep apnea, do not treat any GLP-1 medicine as a replacement for your prescribed therapy — and never stop CPAP or another OSA treatment without medical advice.

Weight loss, sleep apnea, and not stopping CPAP on your own

If you are losing weight on Ozempic and you have OSA, your apnea may genuinely improve — but improvement is not the same as cure, and the decision to change OSA treatment belongs with your clinician, guided by objective testing. The standard of care is to confirm a change in apnea severity with a sleep study before stepping down therapy, not to assume the problem has resolved because you feel better or have lost weight.

  • Do not stop CPAP (or another OSA treatment) on your own. Even with meaningful weight loss, OSA can persist; stopping abruptly without medical advice can bring back the breathing interruptions, daytime sleepiness, and cardiovascular strain that the therapy was protecting against.[1]
  • Let a sleep study guide any change. If you think your apnea has improved, your prescriber can arrange repeat testing to measure it objectively before adjusting CPAP pressure or considering whether therapy can be reduced.[3]
  • Treat the GLP-1 medicine as a complement, not a swap. In the SURMOUNT-OSA program, tirzepatide was studied both with and without CPAP — the medicine and existing therapy were not framed as mutually exclusive, and the weight loss works alongside, not instead of, proper OSA care.[1]
  • Report worsening daytime symptoms. Loud snoring, witnessed pauses in breathing, morning headaches, and excessive daytime sleepiness are reasons to be evaluated for sleep apnea or to revisit existing treatment — these warrant a clinical conversation regardless of weight changes.[3]

Practical, prescriber-directed ways to protect your sleep

Because most Ozempic-related sleep disruption is indirect — traced to nighttime GI symptoms, overnight low blood sugar, under-eating, or anxiety — the fixes target those drivers. The following are general, commonly-discussed strategies, and all of them are prescriber-directed. Do not change your Ozempic dose, start supplements, or adjust other medications without talking to your clinician.

  • Keep a consistent sleep schedule and basic sleep hygiene. Regular bed and wake times, a cool dark room, and winding down without screens give your body the best chance to adapt while it adjusts to the medication.
  • Time your meals to reduce nighttime GI symptoms. Lighter, earlier evening meals — and avoiding large, fatty, or spicy meals close to bedtime — can cut the nausea and reflux that interrupt sleep, since semaglutide slows stomach emptying.[4]
  • Manage overnight low-blood-sugar risk with your prescriber. If you also take insulin or a sulfonylurea, ask your clinician whether the dose or timing should change to reduce night-time lows that cause sweating and waking; do not self-adjust those medications.[4]
  • Eat enough during the day. A strong appetite suppressant makes it easy to under-fuel; regular, protein-forward, balanced meals even when you are not hungry help prevent the hunger and metabolic dips that disturb rest.[4]
  • Mind your dose-escalation weeks. GI side effects, and any sleep disruption traveling with them, tend to be heaviest just after each dose increase; your prescriber can hold you at the current dose longer if a step is rough.[4]
  • Seek help for persistent insomnia or signs of sleep apnea. Sleep trouble that does not settle, or symptoms like loud snoring, witnessed breathing pauses, gasping, or heavy daytime sleepiness, deserve a clinical evaluation rather than being chalked up to the medication.[3]

For the full list of what's common versus serious on this medicine, see Ozempic side effects, and for the basics of how the drug works and who prescribes it, see the Ozempic drug page. Many people also report vivid dreams or nightmares — the honest, REM-sleep explanation is here.

The bottom line

Ozempic and sleep is a two-way story. Insomnia is not a prominently labeled side effect, and the sleep disruption people do report is usually indirect — nighttime GI symptoms, overnight low blood sugar (mostly with insulin or a sulfonylurea), under-eating, or anxiety — and therefore usually fixable with your prescriber's help.[4] At the same time, the weight loss GLP-1 medicines drive often improves sleep, especially by reducing obstructive sleep apnea severity; that benefit is well enough established that the related drug tirzepatide (Zepbound) is now FDA-approved for moderate-to-severe OSA in adults with obesity.[1] Semaglutide is not specifically OSA-approved, but the same weight-loss pathway helps.[2][3] The practical playbook is steady sleep habits, meal timing that limits nighttime GI symptoms, careful management of low-blood-sugar risk, eating enough during the day, and — crucially — never stopping CPAP or other OSA therapy without medical advice.

Frequently Asked Questions

Insomnia is not a prominently labeled common side effect of semaglutide — it doesn't appear as a headline adverse reaction the way nausea, diarrhea, vomiting, and constipation do. When people do sleep poorly after starting Ozempic, the disturbance is usually indirect: nighttime gastrointestinal symptoms like nausea, reflux, or needing the bathroom; low blood sugar overnight (much more likely if you also take insulin or a sulfonylurea, and able to cause night sweats and waking); under-eating during the day; or anxiety about a new medicine. These reports are largely anecdotal or secondary rather than a direct drug effect, which means they're usually addressable by fixing the underlying driver with your prescriber's help.
Often, yes — through weight loss. Obstructive sleep apnea is strongly linked to excess weight, so losing weight tends to reduce its severity, with fewer breathing interruptions and better-quality sleep. The clearest trial evidence is from SURMOUNT-OSA, which tested the related GLP-1/GIP medicine tirzepatide in adults with obesity and moderate-to-severe OSA and found a large reduction in the apnea-hypopnea index; on that basis the FDA approved Zepbound (tirzepatide) for moderate-to-severe OSA in adults with obesity in December 2024. An earlier trial with liraglutide showed the same principle. Ozempic (semaglutide) is not specifically approved for sleep apnea, but because the benefit tracks with weight loss, semaglutide-associated weight loss similarly tends to reduce OSA severity.
No — Ozempic (semaglutide) is not specifically FDA-approved for obstructive sleep apnea. The drug approved to treat moderate-to-severe OSA in adults with obesity is tirzepatide, sold as Zepbound, which received that approval in December 2024 on the strength of the SURMOUNT-OSA trial. Semaglutide drives meaningful weight loss, and since the OSA benefit largely follows the weight loss, it tends to help in practice, but it does not carry an OSA indication on its label.
Not on your own. Even with meaningful weight loss, sleep apnea can persist, and stopping CPAP or another OSA treatment abruptly without medical advice can bring back breathing interruptions, daytime sleepiness, and cardiovascular strain. The right approach is to let a sleep study objectively measure any change in your apnea severity before your clinician adjusts or steps down therapy. Treat the GLP-1 medicine as a complement to proper OSA care, not a replacement, and always make changes to CPAP with your clinician.
Night-time waking and night sweats on Ozempic are most often a sign of low blood sugar overnight, which is much more likely if you also take insulin or a sulfonylurea. They can also stem from nighttime gastrointestinal symptoms (nausea or reflux), under-eating during the day, or anxiety. If you have these symptoms, raise them with your prescriber — they can review whether your insulin or sulfonylurea dose or timing should change and help you treat and prevent lows. Do not self-adjust those medications.
Keep a consistent sleep schedule and basic sleep hygiene (regular bed and wake times, a cool dark room, winding down without screens). Eat lighter, earlier evening meals to limit the nausea and reflux that interrupt sleep, since semaglutide slows stomach emptying. Eat enough during the day so hunger and metabolic dips don't disturb rest, and if you take insulin or a sulfonylurea, ask your prescriber whether the dose or timing should change to reduce overnight lows. Sleep disruption tends to be heaviest just after each dose increase, so your prescriber can hold the current dose longer if a step is rough. Seek a clinical evaluation for persistent insomnia or signs of sleep apnea like loud snoring, witnessed breathing pauses, or heavy daytime sleepiness.
Ozempic is a once-weekly injection, so the day of the week matters more than the time of day. The label allows injecting on the same day each week at any time, with or without food. Because semaglutide has a half-life of approximately one week, the time of day within that weekly cycle does not meaningfully change efficacy or how the drug interacts with sleep. Some people choose a low-demand day - a weekend morning or a day with a lighter schedule - so that if post-injection nausea or fatigue occurs they have more flexibility to rest; others inject in the evening for the same reason. There is no clinical evidence that nighttime versus morning dosing changes outcomes, and the choice comes down to personal routine and tolerability - discuss any timing concerns with your prescriber.

References

  1. 1.Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) — randomized controlled trial showing a large reduction in the apnea-hypopnea index; basis for the December 2024 FDA approval of tirzepatide (Zepbound) for moderate-to-severe OSA in adults with obesity. New England Journal of Medicine (PMID 38912654). 2024. https://pubmed.ncbi.nlm.nih.gov/38912654/
  2. 2.Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial — GLP-1-associated weight loss reduced OSA severity versus placebo. International Journal of Obesity (PMID 27005405). 2016. https://pubmed.ncbi.nlm.nih.gov/27005405/
  3. 3.El-Solh AA, Lawson Y, Attai P. Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review — the airway benefit travels with the weight loss. Expert Opinion on Pharmacotherapy (PMID 39621418). 2025. https://pubmed.ncbi.nlm.nih.gov/39621418/
  4. 4.Novo Nordisk Inc. OZEMPIC (semaglutide) injection, for subcutaneous use — US Prescribing Information, §6 Adverse Reactions and §5 Warnings and Precautions (hypoglycemia with insulin/secretagogues, delayed gastric emptying). Insomnia is not listed among the prominent common adverse reactions. DailyMed (NIH). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  5. 5.U.S. National Library of Medicine (MedlinePlus) Semaglutide Injection — consumer drug information, including common side effects, signs of low blood sugar, and guidance to contact a prescriber if a side effect is severe or does not go away. MedlinePlus (NIH). 2025. https://medlineplus.gov/druginfo/meds/a618008.html

Does Wegovy Cause Insomnia? Sleep Disturbance, the STEP Program, and the FDA Label

Insomnia is not on the Wegovy FDA label at the >=2% threshold used in the STEP program, and the SELECT 17,604-patient safety database surfaced no sleep-related signal. Patient-reported sleep disruption is most plausibly indirect: GI nausea, evening calorie reduction, meal-timing shifts.

13 min read

Does Zepbound Cause Insomnia? Sleep Disturbance, SURMOUNT-OSA, and the FDA Label

Insomnia is not on the Zepbound FDA label at the >=5% threshold, and SURMOUNT-OSA shows tirzepatide improves sleep in obstructive sleep apnea. Patient-reported sleep disruption is most plausibly indirect: GI nausea, evening calorie reduction, meal-timing shifts.

13 min read

Tirzepatide for Sleep Apnea: What SURMOUNT-OSA Showed and the FDA's First-Ever OSA Drug Approval

SURMOUNT-OSA (Malhotra et al., NEJM 2024) is the trial that made Zepbound the first medication ever approved by the FDA for obstructive sleep apnea. We walk through the verified trial data: a 25–29 events-per-hour reduction in AHI, both with and without concurrent CPAP, in adults with moderate-to-severe OSA and obesity.

11 min read

Zepbound for Sleep Apnea (OSA): The Patient Action Plan

If you have moderate-to-severe obstructive sleep apnea and obesity, Zepbound (tirzepatide) became the first FDA-approved medication for OSA in December 2024 based on SURMOUNT-OSA (Malhotra 2024 NEJM): ~25-29 events/hour reduction in apnea-hypopnea index over 52 weeks. Here is…

13 min read

Vivid Dreams or Nightmares on a GLP-1? The Evidence

Some report vivid dreams or nightmares on Ozempic, Wegovy, or Mounjaro. The evidence is thin and indirect — here is the honest, REM-sleep explanation.

9 min read

Cortisol Belly Fat on a GLP-1: Honest Evidence Review

Cushing's syndrome is real but rare (~2-3/million/yr). Subclinical chronic stress modestly elevates cortisol, but the dominant pathway to visceral fat is indirect — reward-driven overeating and sleep loss. Supplements lack RCT support.

12 min read

Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

6.9

YourEra

$99 first-month entry pricing on compounded GLP-1s

6.9

TMates

Nationwide compounded GLP-1 availability including Puerto Rico